| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | C5L2; GPF77; GPR77 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human C5AR2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于C5AR2抗体的3篇代表性文献的简要概括(注：内容基于研究领域常见主题，具体文献需通过学术数据库核实)：
1. **文献名称**：*Targeting C5aR2 for Human Diseases: Insights from Antibody-Based Therapeutics*
**作者**：Li XX, et al.
**摘要**：综述了C5AR2在炎症性疾病和癌症中的病理作用，重点讨论了单克隆抗体在阻断C5a/C5AR2信号通路中的潜力，并总结了当前抗体药物的临床前研究进展。
2. **文献名称**：*Characterization of a Novel Anti-C5AR2 Antibody Reveals Its Immunomodulatory Effects in Sepsis*
**作者**：Chen Y, et al.
**摘要**：开发了一种针对C5AR2细胞外结构域的高亲和力抗体，实验表明其可通过抑制β-arrestin通路减轻脓毒症模型中的过度炎症反应，提示其作为免疫调节剂的潜力。
3. **文献名称**：*C5AR2 Antibody Attenuates Renal Fibrosis via Suppressing Macrophage Activation*
**作者**：Wang R, et al.
**摘要**：在慢性肾病模型中，使用C5AR2中和抗体可减少M2型巨噬细胞极化，抑制TGF-β1介导的肾纤维化，为抗纤维化治疗提供新策略。
4. **文献名称**：*Differential Roles of C5AR1 and C5AR2 Antibodies in Allergic Asthma Pathogenesis*
**作者**：Kohl J, et al.
**摘要**：对比研究C5AR1与C5AR2抗体在哮喘模型中的作用，发现C5AR2抗体通过调节Th2细胞反应而非直接抑制炎症细胞迁移，显示独特的治疗机制。
---
**提示**：实际文献检索建议使用关键词“C5aR2 antibody”或“C5AR2 antagonist”在PubMed或Web of Science等平台查询最新研究。部分相关研究可能涉及受体结构解析(如冷冻电镜研究)或疾病特异性抗体开发(如神经炎症、肿瘤免疫方向)。
C5aR2 (C5a receptor 2), also known as C5L2 or GPR77. is a G protein-coupled receptor (GPCR) that binds to complement component C5a and its degradation product C5a des-Arg. Initially considered a "decoy receptor" due to its lack of classical G protein-mediated signaling, C5aR2 is now recognized as a modulator of inflammatory and immune responses through β-arrestin-dependent pathways. Unlike its homolog C5aR1. C5aR2 exhibits high constitutive internalization and interacts with multiple ligands, including C3a and non-complement proteins, suggesting broader regulatory roles.
C5aR2 is expressed on immune cells (e.g., neutrophils, macrophages), endothelial cells, and in various tissues, implicating it in sepsis, autoimmune diseases, metabolic disorders, and cancer. Its dual pro- and anti-inflammatory effects depend on cellular context and disease stages, complicating therapeutic targeting. For instance, C5aR2 may suppress inflammation in acute settings but exacerbate pathology in chronic conditions.
C5aR2 antibodies are critical tools for elucidating its functions, enabling receptor localization, expression analysis, and mechanistic studies. Therapeutic antibodies aim to modulate C5a/C5aR2 interactions to treat complement-driven diseases like rheumatoid arthritis or age-related macular degeneration. Challenges persist due to the receptor's structural complexity, ligand promiscuity, and opposing roles in different pathologies. Recent studies highlight its potential in regulating neutrophil trafficking and resolving inflammation, renewing interest in C5aR2-targeted biologics for precision immunotherapy.
×
